- Home
- DAN vs KNSA Comparison
DAN vs KNSA Comparison
Compare DAN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAN
- KNSA
- Stock Information
- Founded
- DAN 1904
- KNSA 2015
- Country
- DAN United States
- KNSA United Kingdom
- Employees
- DAN N/A
- KNSA N/A
- Industry
- DAN Auto Parts:O.E.M.
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DAN Consumer Discretionary
- KNSA Health Care
- Exchange
- DAN Nasdaq
- KNSA Nasdaq
- Market Cap
- DAN 2.7B
- KNSA 2.6B
- IPO Year
- DAN N/A
- KNSA 2018
- Fundamental
- Price
- DAN $18.62
- KNSA $38.30
- Analyst Decision
- DAN Buy
- KNSA Strong Buy
- Analyst Count
- DAN 5
- KNSA 7
- Target Price
- DAN $23.60
- KNSA $44.00
- AVG Volume (30 Days)
- DAN 1.6M
- KNSA 403.5K
- Earning Date
- DAN 10-29-2025
- KNSA 10-28-2025
- Dividend Yield
- DAN 2.15%
- KNSA N/A
- EPS Growth
- DAN N/A
- KNSA N/A
- EPS
- DAN N/A
- KNSA 0.07
- Revenue
- DAN $9,938,000,000.00
- KNSA $529,332,000.00
- Revenue This Year
- DAN N/A
- KNSA $37.21
- Revenue Next Year
- DAN N/A
- KNSA $12.07
- P/E Ratio
- DAN N/A
- KNSA $577.26
- Revenue Growth
- DAN 7.73
- KNSA 56.18
- 52 Week Low
- DAN $7.58
- KNSA $17.82
- 52 Week High
- DAN $21.40
- KNSA $39.12
- Technical
- Relative Strength Index (RSI)
- DAN 36.38
- KNSA 63.72
- Support Level
- DAN $19.56
- KNSA $37.35
- Resistance Level
- DAN $20.24
- KNSA $38.83
- Average True Range (ATR)
- DAN 0.51
- KNSA 0.97
- MACD
- DAN -0.23
- KNSA 0.03
- Stochastic Oscillator
- DAN 3.01
- KNSA 76.50
About DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.